{
    "clinical_study": {
        "@rank": "40387", 
        "brief_summary": {
            "textblock": "To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied\n      dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the\n      efficacy of these CTLs in helping the immune system to fight HIV.\n\n      With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and\n      lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs\n      generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the\n      body to recognize HIV more readily and increase immune response against the virus."
        }, 
        "brief_title": "A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and\n      lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs\n      generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the\n      body to recognize HIV more readily and increase immune response against the virus.\n\n      Dendritic cells and lymphocytes are obtained from an HIV-negative sibling. HIV-specific CTLs\n      are generated from these cells and then infused into the HIV-infected patient monthly for 6\n      months. Siblings must be able to donate on multiple occasions, and patients are followed\n      every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HLA A2+.\n\n          -  Other HLA matching with sibling.\n\n          -  CD4 count 100-350 cells/mm3.\n\n          -  No active opportunistic infection or malignancy (other than cutaneous Kaposi's\n             sarcoma).\n\n          -  Current stable antiviral regimen.\n\n          -  Normal lab values and chest x-ray.\n\n        Donor siblings must have:\n\n          -  HLA A2+.\n\n          -  HIV negativity.\n\n          -  Good venous access.\n\n          -  Ability to donate on multiple occasions.\n\n          -  Negative status for hepatitis B and C.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Immunomodulators.\n\n          -  Cytokines.\n\n          -  Systemic steroids.\n\n          -  IV pentamidine.\n\n          -  Investigational drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000824", 
            "org_study_id": "SPIRAT 2"
        }, 
        "intervention": {
            "intervention_name": "Lymphocytes, Activated", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Immunotherapy, Adoptive", 
            "T-Lymphocyte Subsets", 
            "T-Lymphocytes, Cytotoxic", 
            "Dendritic Cells"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "943055107"
                }, 
                "name": "Stanford Univ School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Study of HIV Specific Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients With CD4+ T Cells 100-350 Cells/mm3", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000824"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1995"
    }, 
    "geocoordinates": {
        "Stanford Univ School of Medicine": "37.429 -122.169"
    }
}